Authors want to acknowledge Phillipe Clézardin, INSERM Research Unit 664, Lyon, France, for providing BO2/GFP.2 and BO2f11 breast cancer cells; Amgen for providing RANKL and the anti-RANK antibody N-2B10; and Inês Luis and William C. Dougall for reviewing the manuscript. Here, TNFSF11 is linked to breast cancer.